Last reviewed · How we verify

Imodium — Competitive Intelligence Brief

Imodium (loperamide) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antidiarrheal (peripheral opioid agonist). Area: Metabolic.

marketed Antidiarrheal (peripheral opioid agonist) Aldehyde oxidase, Cocaine esterase, D(4) dopamine receptor Metabolic Small molecule Live · refreshed every 30 min

Target snapshot

Imodium (loperamide) — Johnson & Johnson (McNeil Consumer Healthcare). Peripheral mu-opioid receptor agonist that slows intestinal motility and increases fluid absorption without crossing the blood-brain barrier.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Imodium TARGET loperamide Johnson & Johnson (McNeil Consumer Healthcare) marketed Antidiarrheal (peripheral opioid agonist) Aldehyde oxidase, Cocaine esterase, D(4) dopamine receptor 1976-12-28

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antidiarrheal (peripheral opioid agonist) class)

  1. Johnson & Johnson (McNeil Consumer Healthcare) · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Imodium — Competitive Intelligence Brief. https://druglandscape.com/ci/loperamide. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: